Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V.

Blood. 2002 Dec 15;100(13):4615-21. Epub 2002 Aug 8.

PMID:
12393684
2.

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.

Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barillé S.

Blood. 2001 Dec 15;98(13):3527-33.

PMID:
11739153
3.

IL-6 upregulates its own receptor on some human myeloma cell lines.

Thabard W, Collette M, Mellerin MP, Puthier D, Barillé S, Bataille R, Amiot M.

Cytokine. 2001 Jun 21;14(6):352-6.

PMID:
11497497
4.
5.

Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.

Barillé S, Collette M, Thabard W, Bleunven C, Bataille R, Amiot M.

Cytokine. 2000 Sep;12(9):1426-9.

PMID:
10976008
6.

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.

Derenne S, Amiot M, Barillé S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R.

J Bone Miner Res. 1999 Dec;14(12):2048-56.

7.

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

Puthier D, Derenne S, Barillé S, Moreau P, Harousseau JL, Bataille R, Amiot M.

Br J Haematol. 1999 Nov;107(2):392-5.

PMID:
10583232
8.

Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.

Barillé S, Bataille R, Rapp MJ, Harousseau JL, Amiot M.

J Immunol. 1999 Nov 15;163(10):5723-8.

9.

Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.

Thabard W, Barillé S, Collette M, Harousseau JL, Rapp MJ, Bataille R, Amiot M.

Clin Cancer Res. 1999 Oct;5(10):2693-7.

10.

CD130 rather than CD126 expression is associated with disease activity in multiple myeloma.

Barillé S, Thabard W, Robillard N, Moreau P, Pineau D, Harousseau JL, Bataille R, Amiot M.

Br J Haematol. 1999 Aug;106(2):532-5.

PMID:
10460618
11.

Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy.

Puthier D, Pellat-Deceunynck C, Barillé S, Robillard N, Rapp MJ, Juge-Morineau N, Harousseau JL, Bataille R, Amiot M.

Leukemia. 1999 Feb;13(2):289-94.

12.

The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.

Pellat-Deceunynck C, Barillé S, Jego G, Puthier D, Robillard N, Pineau D, Rapp MJ, Harousseau JL, Amiot M, Bataille R.

Leukemia. 1998 Dec;12(12):1977-82.

13.

CD28, a marker associated with tumoral expansion in multiple myeloma.

Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP, Barillé S, Rapp MJ, Harousseau JL, Amiot M, Bataille R.

Clin Cancer Res. 1998 Jun;4(6):1521-6.

14.

Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells.

Barillé S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M.

Blood. 1997 Aug 15;90(4):1649-55.

PMID:
9269785
15.

Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.

Puthier D, Bataille R, Barillé S, Mellerin MP, Harousseau JL, Ponzio A, Robillard N, Wijdenes J, Amiot M.

Blood. 1996 Dec 15;88(12):4659-66.

PMID:
8977259
16.

Ectopic secretion of osteocalcin, the major non-collagenous bone protein, by the myeloma cell line NCI-H929.

Barille S, Pellat-Deceunynck C, Bataille R, Amiot M.

J Bone Miner Res. 1996 Apr;11(4):466-71.

PMID:
8992877
17.
18.

Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.

Pellat-Deceunynck C, Barillé S, Puthier D, Rapp MJ, Harousseau JL, Bataille R, Amiot M.

Cancer Res. 1995 Aug 15;55(16):3647-53.

19.

Fluoroquinolone use and fluoroquinolone resistance: is there an association?

Richard P, Delangle MH, Merrien D, Barillé S, Reynaud A, Minozzi C, Richet H.

Clin Infect Dis. 1994 Jul;19(1):54-9.

PMID:
7948558

Supplemental Content

Loading ...
Support Center